Build a Spinal Cord Stimulator Device Company

1. 1

   Find a differentiated device thesis

   The SCS market is real and growing (roughly $2.95B in 2026 to $5.34B by 2035) but concentrated among Medtronic, Abbott, Boston Scientific, and Nevro, so a new entrant must be meaningfully differentiated: a novel waveform or closed-loop feedback, a smaller or MRI-conditional implant, better leads, or a lower-cost platform. Undifferentiated me-too devices cannot overcome incumbent scale and physician relationships. Define the clinical and technical edge before anything else. The thesis is the whole venture.

2. 2

   Assemble the team and the capital

   This is a capital-intensive, expertise-dense venture requiring neuromodulation engineers, regulatory affairs, clinical operations, and quality systems, plus tens of millions in funding to reach approval. Investors underwrite the team and the differentiation, not just the market size. Be honest that revenue is years away and the R&D, clinical, and regulatory spend comes first. This is a fund-and-build medtech company, not a lean startup.

3. 3

   Plan the FDA Class III (PMA) pathway

   Implantable SCS devices are Class III and typically require a Premarket Approval (PMA) supported by clinical trials proving safety and effectiveness, the most demanding FDA pathway. Build the regulatory and clinical plan early, including design controls and an ISO 13485 quality system, because the pathway defines the timeline and the burn. Regulatory strategy is not a late-stage task; it shapes the device design. Engage FDA early through pre-submission meetings.

4. 4

   Build quality-system manufacturing

   Manufacturing an implantable device demands a validated, ISO 13485 quality system, sterile and biocompatible processes, and rigorous supply-chain control, because a field failure in an implant is catastrophic clinically and legally. Contract manufacturing or an owned line both require the same quality rigor. Post-market surveillance and traceability are ongoing obligations. Quality is the license to operate in Class III devices.

5. 5

   Secure reimbursement and physician adoption

   A device only sells if it is reimbursed and if implanting physicians adopt it, so build a reimbursement strategy (Medicare and commercial coverage and coding) and a clinical-evidence and key-opinion-leader plan alongside the regulatory work. The incumbents win partly on established codes and physician relationships, so your evidence and economics must give surgeons a reason to switch. Reimbursement and adoption, not approval alone, are what turn the device into revenue. Plan them from the start.

Do not take our word for the money. Put your own numbers in and see what this idea has to earn before it works. Free, instant, no account needed.

Best for: Funded medtech founders with neuromodulation, regulatory, and clinical-trial capability

Not for: Anyone without access to serious capital and deep neuromodulation and regulatory expertise, or who wants a lean, fast launch. This is a fund-and-build Class III medtech company with revenue years out and no guarantees.